YAĞMUR ÜNVER, ESABİ BAŞARAN KURBANOĞLU, ORHAN ERDOĞAN

Expression, purification, and characterization of recombinant human paraoxonase 1 (rhPON1) in Pichia pastoris

The main purpose of the present study was to perform the expression in Pichia pastoris X-33 of the human paraoxonase 1 (hPON1) enzyme, which is a mammalian serum protein. Extracellular hPON1 enzyme was expressed with the pPICZ?A vector using a strong AOX promoter, and enzyme secretion in the fermentation medium was achieved by means of Saccharomyces cerevisiae alpha factor signal sequence. The recombinant cells were grown in a shaking flask containing production medium. SDS-PAGE and Western blot analysis illustrated that the molecular mass of extracellular hPON1 enzyme produced by the recombinant P. pastoris strain was 59.1 kDa. Biochemical characterization of the enzyme was carried out after purification with a Probond affinity column. The purified paraoxonase 1 activity was determined as 18.9 U/mL; however, enzyme activity reached 31.27 U/mL at the end of the characterization studies. According to the results, KM and Vmax values were 0.025 mM and 28.4 U/mL, respectively, in 100 mM glycine-NaOH buffer (pH 10) containing 2 mM Ca2+ at 15 °C. This is the first report on the expression and production of hPON1 in P. pastoris.

Anahtar Kelimeler:

Pichia pastoris X-33, hPON1, recombinant protein, purification, characterizatio

Expression, purification, and characterization of recombinant human paraoxonase 1 (rhPON1) in Pichia pastoris

Keywords:

Pichia pastoris X-33, hPON1, recombinant protein, purification, characterizatio,

PDF

___

0.5 38 0.81 0.8 0.6 0.025 This study References
Almeida MS, Cabral KS, de Medeiros LN, Valente AP, Almeida F, Kurtenbach E (2001). cDNA cloning and heterologous expression of functional cysteine-rich antifungal protein Psd1 in the yeast Pichia pastoris. Arch Biochem Biophys 395: 199‒207.
Bensadoun A, Weinstein D (1976). Assays of proteins in the presence of interfering materials. Anal Biochem 70: 241‒250.
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72: 248‒254.
Brondyk WH (2009). Selecting an appropriate method for expressing a recombinant protein. Methods Enzymol 463: 131‒147.
Cereghino JL, Cregg JM (2000). Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 24: 45‒66.
Costa LG, Cole TB, Jarvik GP, Furlong CE (2003). Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54: 371‒392.
Costa LG, Furlong CE (2002). Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Norwell, MA, USA: Kluwer Academic Publishers.
Daly R, Hearn MTW (2005). Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recognit 18: 119‒138.
Draganov DI, La Du NB (2004). Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369: 78‒88.
Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN (2005). Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46: 1239‒1247.
Francis DM, Page R (2010). Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci 61; 5.24: 5.24.1‒5.24.29.
Gan KN, Smolen A, Eckerson HW, La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100‒106.
Gurkan C, Ellar DJ (2005). Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact 4: 33.
Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L et al. (2004). Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11: 412‒419.
Jana S, Deb JK (2005). Strategies for efficient production of heterologous proteins in Escherichia coli. Appl Microbiol Biotechnol 67: 289‒298.
Khersonsky O, Tawfik DS (2005). Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44: 6371‒6382.
Li H, Li N, Gao X, Kong X, Li S, Xu A, Jin S, Wu D (2011). High level expression of active recombinant human interleukin-3 in Pichia pastoris. Protein Expr Purif 80: 185‒193.
Li WF, Costa LG, Richter JR, Hagen T, Shih DN (2000). Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10: 767‒779.
Li Y, Wu S, Ouyang J, Mao L, Li W, Lin H (2012). Expression of insulin-like growth factor-1 of orange-spotted grouper (Epinephelus coioides) in yeast Pichia pastoris. Protein Expr Purif 84: 80‒85.
Li ZG, Moy A, Sohal K, Dam C, Kuo PJ, Whittaker M, Whittaker N, Duzgunes K, Konopka AH, Franz J et al. (2009). Expression and characterization of recombinant human secretory leukocyte protease inhibitor (SLPI) protein from Pichia pastoris. Protein Expr Purif 67: 175‒181.
Lu H, Chu P, Sun M, Qin J (2006). High-level expression of recombinant human paraoxonase 1 Q in silkworm larvae (Bombyx mori). Appl Microbiol Biotechnol 72: 103‒108.
Lu H, Zhu J, Zang Y, Ze Y, Qin J (2006). Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expr Purif 46: 92‒99.
Lusis AJ (2000). Atherosclerosis. Nature 407: 233‒241.
Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM (2005). Heterologous protein production using the Pichia pastoris system. Yeast 22: 249‒270.
Mengwasser KE, Bryant CE, Gay NJ, Gangloff M (2011). LPS ligand and culture additives improve production of monomeric MD-1 and 2 in Pichia pastoris by decreasing aggregation and intermolecular disulfide bonding. Protein Expr Purif 76: 173– 183.
Nilsson B, Bermanmarks C, Kuntz ID, Anderson S (1991). Secretion incompetence of bovine pancreatic trypsin inhibitor expressed in Escherichia coli. J Biol Chem 266: 2970‒2977.
Ostermeier M, DeSutter K, Georgiou G (1996). Eukaryotic protein disulfide isomerase complements Escherichia coli dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds. J Biol Chem 271: 10616‒10622.
Renault F, Chabrière E, Andrieu JP, Dublet B, Masson P, Rochu D (2006). Tandem purification of two HDL associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J Chromatogr B 836: 15‒21.
Rodrigo L, Mackness B, Durington PN, Hernandez A, Mackness MI (2001). Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354: 1‒7.
Shih DM, Gu L, Xia YR, Navab M, Li WF, HamaS, CastellaniLW, FurlongCE, CostaLG, FogelmanAM et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284‒287.
Sorenson RC, Bisagaier CL, Aviram M, Hsu C, La Du BN (1999). Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19: 2214‒2225.
Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE (2008). Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. P Natl Acad Sci USA 105: 12780– 12784.
Suzuki SM, Stevens RC, Richter RJ, Cole TB, Park S, Otto TC, Cerasoli DM, Lenz DE, Furlong CE (2010). Engineering human PON1 in an E. coli expression system. Adv Exp Med Biol 660: 37‒45.